-
Iran likely behind attacks sowing fear among Europe's Jews: experts
-
'Relieved' McGrath claims career first crystal globe in slalom
-
US ski star Shiffrin wins overall World Cup title for sixth time
-
Trump names tech titans to science advisory council
-
Mideast war sparks long queues at Kinshasa petrol stations
-
US TV star details 'agony' over mother's disappearance
-
Tehran receives US plan to end Mideast war, as Iran fires at US carrier
-
Aviation, tourism, agriculture... the economic sectors hit by the war
-
Iran fires at US carrier as backchannel diplomacy aims to end war
-
Salah's long goodbye brings curtain down on golden era for Liverpool
-
Monaco: city of vice and a few virtues
-
AI making cyber attacks costlier and more effective: Munich Re
-
Defying Israeli bombs, Lebanese hold out in southern city of Tyre
-
War-linked power crunch pushes Sri Lanka to four-day week
-
Hungary says will phase out gas deliveries to Ukraine
-
Oil prices tumble, stocks rally on Mideast peace hopes
-
Maybach: Between Glory and a Turning Point
-
German business morale falls as war puts recovery on ice: survey
-
Labubu maker Pop Mart's shares fall 23% despite surging earnings
-
ECB won't be 'paralysed' in face of energy shock: Lagarde
-
Iran hits targets across Middle East after Trump signals talks progress
-
McEvoy says best is to come after breaking long-standing swim record
-
Goat vs gecko: A tiny Caribbean island faces wildlife showdown
-
Japan PM asks IEA chief to prepare additional 'coordinated release' of oil
-
Hungary's hard-pressed LGBTQ people say Orban exit is only half battle
-
Belarus leader visits North Korea for first time
-
'No heavier burden': the decades-long search for Kosovo war missing
-
Exotic pet trade thrives in China despite welfare concerns
-
Iran fires missile salvo after Trump signals progress in talks
-
BTS concert drew 18.4 million viewers, says Netflix
-
OSCE's 'chaotic' Ukraine evacuation put staff at risk: leaked report
-
Top WTO official sounds fertiliser warning over Middle East war
-
France and Brazil weigh up World Cup prospects in glamour friendly
-
Italy hoping to end World Cup pain as play-offs loom
-
Dirty diapers born again in Japan recycling breakthrough
-
Verstappen's Japan GP win streak under threat as Mercedes dominate
-
Crude tumbles, stocks rally on hopes for Iran war de-escalation
-
Gauff outlasts Bencic to reach Miami semi-finals
-
'Hero' Australian dog who saved 100 koalas retires
-
Underdogs chase World Cup berths in Mexico playoff tournament
-
Pope heads to tiny Catholic Monaco
-
Meet the four astronauts set to voyage around the Moon
-
Artemis 2 Moon mission: a primer
-
It's go time: historic Moon mission set for lift-off
-
Denmark's PM Mette Frederiksen, tenacious and tough on migration
-
OpenAI kills Sora video app in pivot toward business tools
-
Danish PM's left-wing bloc wins election, but no majority
-
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
-
Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D
-
Datavault AI Partners with Rising British Heavyweight Moses Itauma
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC